Passage BIO Files Annual Report
Ticker: PASG · Form: ARS · Filed: Apr 7, 2026 · CIK: 0001787297
| Field | Detail |
|---|---|
| Company | Passage Bio, Inc. (PASG) |
| Form Type | ARS |
| Filed Date | Apr 7, 2026 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: annual-report, sec-filing, biotechnology
TL;DR
Passage BIO filed its 2025 ARS on 4/7/26. Check it for financials.
AI Summary
Passage BIO, Inc. filed its Annual Report to Security Holders (ARS) on April 7, 2026, for the period ending December 31, 2025. The report details the company's financial and operational status for the fiscal year. Passage BIO, Inc. is a biotechnology company focused on biological products.
Why It Matters
This filing provides shareholders and potential investors with a comprehensive overview of Passage BIO's performance and financial health for the fiscal year 2025.
Risk Assessment
Risk Level: low — This is a routine annual filing providing historical information, not indicating new risks.
Key Players & Entities
- Passage BIO, Inc. (company) — Filer
- 0001787297 (company) — CIK
- 2026-04-07 (date) — Filing Date
- 2025-12-31 (date) — Period of Report
FAQ
What is the CIK number for Passage BIO, Inc.?
The CIK number for Passage BIO, Inc. is 0001787297.
When was the ARS filing accepted by the SEC?
The ARS filing was accepted by the SEC on April 7, 2026.
What period does this Annual Report to Security Holders cover?
This report covers the period ending December 31, 2025.
What is the business address of Passage BIO, Inc.?
The business address is ONE COMMERCE SQUARE, 2005 MARKET STREET, 39TH FLOOR, PHILADELPHIA PA 19103.
What SIC code is associated with Passage BIO, Inc.?
The SIC code is 2836 for Biological Products, (No Diagnostic Substances).
Filing Details
This Form ARS (Form ARS) was filed with the SEC on April 7, 2026 regarding Passage BIO, Inc. (PASG).